Last reviewed · How we verify
Dose 1 JKB-122
Dose 1 JKB-122 is a Small molecule drug developed by TaiwanJ Pharmaceuticals Co., Ltd. It is currently in Phase 2 development. Also known as: JKB-122.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Dose 1 JKB-122 |
|---|---|
| Also known as | JKB-122 |
| Sponsor | TaiwanJ Pharmaceuticals Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Pharmacokinetic Study of JKB-122 Tablets Compared to Capsule (PHASE1)
- A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dose 1 JKB-122 CI brief — competitive landscape report
- Dose 1 JKB-122 updates RSS · CI watch RSS
- TaiwanJ Pharmaceuticals Co., Ltd portfolio CI
Frequently asked questions about Dose 1 JKB-122
What is Dose 1 JKB-122?
Who makes Dose 1 JKB-122?
Is Dose 1 JKB-122 also known as anything else?
What development phase is Dose 1 JKB-122 in?
Related
- Manufacturer: TaiwanJ Pharmaceuticals Co., Ltd — full pipeline
- Also known as: JKB-122
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing